View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 7, 2021updated 13 Jul 2022 9:05am

Triall enters partnership to anchor Covid-19 data to blockchain

Triall will leverage LTO Network's blockchain technology and infrastructure to anchor the research data.

Dutch start-up Triall has entered a new partnership with local blockchain companies LTO Network and Sphereon to anchor Covid-19 research data.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The move is aimed to preserve the integrity and security of clinical trial data.

As agreed, Triall will leverage LTO Network’s blockchain technology and infrastructure to anchor the research data to the blockchain. The collaboration will start with a Covid-19 clinical trial and later can be expanded to other studies.

Triall CEO Hadil Es-Sbai said: “The ongoing Covid-19 crisis has sparked digital transformation across the pharmaceutical landscape.

“Our collaboration with LTO Network will pave the way for a range of innovative e-clinical software solutions supporting decentralised clinical trials.”

Clinical trials usually generate vast amounts of data and can continue for years. Some of the common challenges of such trials include increasing costs, recordkeeping failures, delays, and a lack of oversight.

According to LTO Network, some of the blockchain properties such as decentralisation, security and privacy, will help in addressing such issues and consolidating the fragmented landscape of clinical trial stakeholders and software systems.

The use of blockchain will also prevent tampering and ensure transparency and integrity of research data.

LTO Network CEO Rick Schmitz said: “Together, we are building the world’s first clinical-trial software powered by the blockchain that will secure and streamline the development of a safe and affordable future in medicine.”

Triall focuses on creating a digital ecosystem of blockchain-integrated software solutions to facilitate the development of new vaccines and therapeutics during clinical trials. According to the company website, Triall’s software is created by clinical trial professionals.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena